The system to malignant tumor treatment diverges considerably between the America and Continental Europe . In the US , access care is often linked to individual insurance , leading in possibly substantial costs and inconsistent results . Unlike, EU healthcare generally offer broad access through publicly backed medical programs, which focuses on pr

While both the United States and Europe strive to provide optimal cancer care, their methods differ noticeably. The US often emphasizes advanced treatments, sometimes leading to higher costs. In contrast, European systems tend to prioritize holistic care and cost-effectiveness, highlighting early screening. This can result in varied patient experie